HUMAN PAPILLOMA VIRUS VACCINATION IN THE UNITED STATES
DOI:
https://doi.org/10.46793/PP170305008KKeywords:
human papilloma virus, vaccine, prevention, complianceAbstract
Human Papilloma Virus (HPV) is the most common sexually transmitted virus in the United States with the highest affected population being adolescents and young adults. Most HPV infections resolve spontaneously, but they are also known to cause genital warts as well as cervical, penile, and anal cancers. In the United States, HPV causes 7,000 male cancers and 15,000 female cancers annually. Due to this high prevalence, the American Academy of Pediatrics recommends vaccinating all males and females against HPV starting between the ages of 11 and 12, and as early as 9 years old. The current clinical indications, vaccine efficacy, and physician and patient compliance will be presented.
References
Committee on Infectious Disease. HPV Vaccine Recommendations. Pediatrics. 2012; 129: 602-605. DOI:10.1542/peds.2011-3865.
Jenco M. CDC Approves 2-dose HPV Vaccine Schedule. AAP News. December 15, 2016.
Allison M et al. Primary Care Physicians’ Perspectives About HPV Vaccine. Pediatrics. 2016; 137: 1-9. DOI: 10.1542/peds.2015-2488.
Niccolai L et al. The Role of Cognitive Bias in Suboptimal HPV Vaccine Uptake. Pediatrics. 2016; 138: 1-3. DOI: 10.1542/peds.2016-1537.
Garland S et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systemic Review of 10 Years of Real-world Experience. Clinical Infectious Disease. 2016; 63: 519-527. DOI: 10.1093/cid/ciw354.
Markowitz L et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016: 1-9. DOI: 10.1542/peds.2015-1968
